Boston Scientific Corporation

Valuation Analysis

About the Company

Boston Scientific Corporation en bref

Boston Scientific Corporation (BSX) is currently trading at 39,49 € with a market capitalization of 58,7 Md €. The trailing P/E ratio stands at 18.95x, with a forward P/E of 12.16x. The 52-week range spans from 38,74 € to 95,46 €; the current price is 58.6% below the yearly high. Year-over-year revenue growth stands at +11.6%. The net profit margin stands at 17.29%.

💰 Dividende

Boston Scientific Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

30 analystes évaluent Boston Scientific Corporation (BSX) au consensus : Achat Fort. L'objectif de cours moyen est de 67,21 €, soit un potentiel de +70.2% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 47,95 € à 92,41 €.

Boston Scientific Corporation : la thèse d'investissement en détail

Boston Scientific Corporation (BSX) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 11.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 100% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 68.94%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Valorisation en contexte

With a PEG ratio of 0.57, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 12.16x is meaningfully below the trailing 18.95x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 70.2% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Boston Scientific Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.